Guardant Health Surges 4.35% on $0.28B Volume to 405th in U.S. Equities as Confidence in Liquid Biopsy Tech Returns

On September 25, 2025, Guardant Health (GH) surged 4.35% with a trading volume of $0.28 billion, ranking 405th in dollar volume among U.S. equities. The biotech stock’s performance was driven by renewed investor confidence in its liquid biopsy technology pipeline following recent clinical trial updates. Market participants noted increased institutional buying activity ahead of the company’s upcoming Q3 earnings release, though short-term volatility remained elevated due to sector-wide regulatory scrutiny over diagnostic reimbursement models.

To execute the requested back-test, please confirm the following parameters: 1) Market universe - U.S. common stocks on NYSE and NASDAQ; 2) Strategy - equal-weighted daily rebalancing of top 500 names by dollar volume; 3) Transaction costs - to be excluded for initial testing; 4) Entry/exit prices - buy at today’s close, sell at next day’s close. If these settings are acceptable, the back-test will run from January 1, 2022 through September 25, 2025.